Dutch molecular diagnostics conglomerate Qiagen launched its new human papillomavirus test in India for women in areas with limited healthcare infrastructure. The company is touting the careHPV test as the first designed specifically with this patient group in mind.
Qiagen has rolled out a new test for high-risk human papillomavirus in India designed to screen women in areas with limited healthcare infrastructure.
Qiagen and Exosome Diagnostics will partner to develop innovative, noninvasive molecular in vitro diagnostics to detect lung cancer and other malignancies.
Qiagen won Chinese regulatory approval for a next-generation tuberculosis test and expects a commercial rollout there in the early part of 2014.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Qiagen plans to move ahead with a $100 million share repurchase program in the wake of improved revenue and sales in the 2013 second quarter on nearly all fronts.
Qiagen's string of companion diagnostics success continues with the FDA's approval of a molecular test for lung cancer, OK'd alongside a targeted Boehringer Ingelheim drug.
Qiagen has licensed a few a cancer biomarkers the company said will help expand its heft in the lucrative companion diagnostics world, targeting gene expressions that jibe with in-development therapies.
Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.